Neuroblastoma is the second most common pediatric malignancy, characterized by a high rate of unexplained spontaneous remissions. Much progress has been made in understanding neuroblastoma differentiation triggered by certain agents such as retinoic acid. However, little is known about the signalling pathways that lead to differentiation of neuroblastoma cells due to serum withdrawal. We found that in Neuro2a neuroblastoma cells, EGFR, ERK1/2 and Akt showed increased phosphorylation after serum withdrawal, and that the activation of EGFR was necessary for the activation of Akt and ERK1/2. Inhibition of EGFR, ERK1/2 and PI3K blocked neuroblastoma differentiation after serum withdrawal. Interestingly, addition of high-density lipoprotein (HDL) abrogated serum-withdrawal induced neuroblastoma differentiation, as well as the activation of EGFR. Our results demonstrate a novel role for serum-derived lipoproteins in the control of receptor tyrosine kinase activity.
Introduction
Neuroblastomas arise from precursor cells of the neural crest (Pahlman, 2000) . Presumably, neoplastic transformation is induced by molecular defects affecting signalling pathways during the maturation of these progenitor cells to postmitotic sympathetic neurons (Brodeur, 2003) . Neuroblastomas exhibit the fascinating potential to differentiate spontaneously and regress. The mechanisms of this process are unknown.
Several agents have been identified which induce neuronal differentiation of neuroblastoma cells in vitro, including retinoic acid (RA), and growth factors such as neurotrophins (Nakagawara, 2001) . Previous work exploring downstream pathways has firmly established that neurotrophins signal via receptor tyrosine kinases (RTKs), which in turn activate the Ras/Raf/MEK/ ERK1/2 and PI3K/Akt signalling modules, leading to the execution of complex transcriptional programs necessary for growth arrest and morphological differentiation (Segal and Greenberg, 1996) .
Cultured cells are frequently grown in medium containing serum, with the rational that serum contains peptide growth factors, which in turn will facilitate survival and proliferation of cells in vitro. Interestingly, several types of cells including neuroblastoma cell lines are induced to differentiate by removal of serum from the culture medium (Schubert et al., 1969; Seeds et al., 1970) . However, peptide growth factors are not the only important serum components. Serum also contains lipoproteins, which represent the major transport shuttles for lipids such as cholesterol and triglycerides in body fluids. Conventionally, lipoproteins and their receptors are not considered signalling molecules. Recently, considerable evidence has accumulated supporting alternative views. For instance, reelin binds to the very low-density lipoprotein (VLDL) receptor and ApoE receptor 2 (ApoER2), triggering signalling important for developmental cerebellar patterning. In addition, high-density lipoprotein (HDL) promotes proliferation of tumour cells (Gospodarowicz et al., 1982; Cao et al., 2004) and stimulates multiple signalling pathways (Walter et al., 1995; Grewal et al., 2003) . It is also generally accepted that one of the major cargo of lipoproteins, cholesterol, plays an important role in signal transduction, as cholesterol depletion disrupts lipid rafts, which serve as scaffolds for RTKs and other signalling intermediates. Lipid rafts are now recognized to be sites of localized transduction of several extracellular stimuli. Disruption of rafts by cholesterol depletion might either inhibit or trigger RTK signalling (Paratcha and Ibanez, 2002) . The latter is the case for the epidermal growth factor receptor (EGFR), as disruption of rafts by depletion of cholesterol leads to catalytic auto-activation and ligand-independent activation of this RTK (Furuchi and Anderson, 1998; Chen and Resh, 2002; Ringerike et al., 2002; Roepstorff et al., 2002; Westover et al., 2003) .
Several neuroblastoma cell lines differentiate after serum deprivation. In contrast to the treatments mentioned above, the downstream signalling mechanisms that are activated in neuroblastoma cells after serum withdrawal are largely unknown. In the present study, we first revealed that serum deprivation induces Neuro2a neuroblastoma cell differentiation by activating EGFR, Akt and ERK1/2. Unexpectedly, the addition of HDL blocked both Neuro2a cell differentiation and activation of EGFR induced by serum deprivation. Our results point towards a previously unrecognized role of HDL in the control of EGFR activity.
Results

Neuro2a neuroblastoma cells differentiate after serum withdrawal
As exemplified in Figure 1a , Neuro2a cells grown in DMEM containing 10% fetal calf serum (FCS) are undifferentiated. In contrast, when their normal growth medium was removed and substituted by DMEM containing 0.1% BSA, neuronal differentiation occurred. Already after 30 min, cellular processes became apparent. After 24 h of serum-free culture, the cells had established a dense network of neurites ( Figure 1a) . Accordingly, using biochemical methods, we found a rapid upregulation of the neuronal marker proteins NeuN and chromogranin-B with increases being apparent after 30 min, a time point corresponding to the observed morphological differentiation (Figure 1b and c). In contrast, differentiation did not lead to increases of tubulin, as previously reported (Diaz-Nido et al., 1991) . Importantly, replacement of the culture medium of undifferentiated Neuro2a cells grown in DMEM containing 10% fetal calf serum with fresh medium of the same composition did not induce differentiation (data not shown), indicating that the change of medium itself had no effect.
We also examined some other commonly used neuroblastoma cell lines for differentiation after serum withdrawal, and we found that SY5Y and SK-N-SH behaved like Neuro2a (data not shown).
Dose-response studies revealed that serum concentrations of 1% FCS were sufficient to promote proliferation of Neuro2a cells, whereas concentrations of 0.1% FCS biased these cells towards differentiation (Figure 1d ). Differentiated cells were viable for 4 days after serum withdrawal (data not shown). During this time window, cell numbers remained stable as shown by a CyQUANT Cell Proliferation Assay Kit (Molecular Probes; data not shown).
Activation of signalling pathways by serum withdrawal
To determine the signalling pathways responsible for serum withdrawal induced neuroblastoma differentiation, we performed a series of immunoblots probing for the presence of key signalling proteins in lysates of cells grown in full serum (control) and of cells lysed at different time points after serum withdrawal.
As shown in Figure 2 , serum withdrawal induced an increase in activated Akt without concurrent increases in total levels of this kinase. Plateau levels were reached around 30 min, resembling the increases in the differentiation marker NeuN (compare to Figure 1B) . The pAkt levels diminished at later time points (6 h) and became undetectable 24 h after serum withdrawal. Replacement of the culture medium containing full serum with fresh culture medium containing full serum had no effect on pAkt levels (data not shown).
ERK1 and 2 are established mediators of neuronal differentiation in neuroectodermal tumour cells such as PC12 cells. Thus, it appeared necessary to examine their phosphorylation state after serum withdrawal. As shown in Figure 2 , we found increases in pERK1/2 levels within 5 min after serum withdrawal. However, there appears to be a dichotomy for p42 and p44 regarding their time course of activation. Whereas p42 was persistently phosphorylated for at least 48 h after serum withdrawal (with a peak around 6 h), the levels of phosphorylated p44 dropped to levels found in unstimulated cells between 5 min and 2 h after serum withdrawal. The reason for this drop is currently unclear, although it has been observed in other settings (Robinson et al., 1998) . Replacement of the culture medium containing full serum with fresh culture medium containing full serum had no effect on pERK1/2 levels (data not shown).
Raf-1 is a key kinase downstream of a plethora of stimuli such as Ras. As shown in Figure 2 , Raf-1 activation was increased in Neuro2a cells after serum withdrawal, albeit with different kinetics in comparison to Akt and ERK1/2. Raf phosphorylation was observed as early as 5 min after serum withdrawal, and its activation remained constant during the differentiation process.
Next, we examined the total levels and activities of key transcription factors that are known to be involved in neuronal differentiation downstream of Akt and ERK1/2. As shown in Figure 2 , levels of the immediateearly transcription factor c-Fos as well as phosphorylated cAMP-responsive element binding protein (CREB) increased during serum withdrawal induced differentiation. However, we noticed distinct kinetic patterns. Whereas c-Fos peaked around 30 min after 
ERK1/2 and Akt are necessary for serum-withdrawal induced differentiation
To test whether there is a causal relationship between serum-withdrawal induced activation of Akt or mitogen-activated protein kinases (MAPKs) and serumwithdrawal induced differentiation of Neuro2a cells, we applied inhibitors of PI3K (LY294002) and of MEK (PD98059). As shown in Figure 3a , pretreatment with LY294002 or PD98059 for 1 h before serum withdrawal almost completely blocked the differentiation response. The vehicle-control (DMSO) had no effect. The observed lack of differentiation could have been caused either by a specific block of the signalling program leading to differentiation or, alternatively, could have been caused by a compromised viability of LY294002 or PD98059 treated cells. Thus, we performed control experiments to check whether the addition of these compounds affected cell survival. Using a LIVE/ DEAD-Viability/Cytotoxicity Kit (Molecular Probes), no increase in the death rate of serum depleted neuroblastoma cells was found after treatment with these inhibitors within the time frame of our experiments (data not shown).
To corroborate the specificity of the results obtained with the pharmacological inhibitors, the role of the PI3K/Akt and Ras/Raf/MEK/ERK1/2 pathways was examined using an alternative approach, transfection with either dominant-negative Akt expression plasmid (DN-Akt/HA) or a dominant-negative Ras expression plasmid (DN-Ras/HA), both of which were tagged with the hemagglutinin influenza virus epitope (HA) to identify transfected cells. As shown in Figure 3b , cells transfected with DN-Akt/HA or DN-Ras/HA did not differentiate after serum withdrawal. Therefore, both PI3K/Akt and MAPK pathways are necessary for differentiation. The higher background when using dominant-negative constructs could be explained by insufficient expression levels in a certain percentage of transfected cells.
Next, we tested whether treatment with LY294002 inhibited the activation of MAPKs or whether PD98059 blocked the phosphorylation of Akt. As shown in Figure 3c and d, the activation of ERK1/2 was blocked by LY294002 whereas PD98059 had no effect on the activation of Akt. As expected, PD98059 blocked phosphorylation of ERK1/2 but not phosphorylation of Akt. Thus, ERK1/2 activation depends on PI3K, but Akt activation does not depend on MAPK pathway in our experimental system.
HDL blocks the serum depletion induced neuroblastoma differentiation
What are the agent(s) contained within FCS whose withdrawal has such a dramatic effect on the morphology of tumour cells? Nirenberg and co-workers (Seeds et al., 1970) started to address this question. These authors tested the ability of serum protein fractions to inhibit serum withdrawal induced neuroblastoma differentiation of C-1300 cells (the parental line of Neuro2a). These authors found that alpha-and beta-globulin fractions were able to block neuroblastoma differentiation after serum withdrawal. So, what is the component of these fractions that is critical for differentiation? One key factor might be cholesterol and lipoproteins, since the fractions described by these authors contain cholesterol-rich lipoproteins. In line with this hypothesis, previous papers reported that depletion of cholesterol promoted neuroblastoma differentiation (Dimitroulakos and Yeger, 1996) and that lipoproteins promote tumour proliferation (Gospodarowicz et al., 1982; Rotheneder and Kostner, 1989) .
To evaluate whether lipoproteins played a role in blocking neuroblastoma differentiation, we tested the effect of lipoprotein-deficient serum (LPDS) on Neuro2a cells. Surprisingly, we found that substitution of medium containing 10% full serum by medium containing 10% LPDS triggered neuroblastoma differentiation in a similar way as serum-withdrawal (Figure 4a ). Effect of serum withdrawal on the activation of kinases and transcription factors. Neuro2a cells were subjected to serum withdrawal for different times. Subsequently, cells were lysed, equal amounts of protein lysates were subjected to SDS-PAGE, and immunoblots were probed with the indicated antibodies HDL and low-density lipoprotein (LDL) are two major members of the lipoprotein family. Therefore, we next investigated whether the removal of HDL or LDL might be responsible for serum-withdrawal induced differentiation of neuroblastoma cells. Thus, we added purified HDL or LDL (standardized according to their cholesterol concentration) to neuroblastoma cells undergoing serum withdrawal, and assessed if this would block their differentiation. As shown in Figure 4b , HDL treatment (at cholesterol concentrations of 10, 40 or 80 mg/ml) inhibited differentiation in a dose-dependent manner, without compromising viability of cells (data not shown). Addition of 80 mg/ml cholesterol in the form of HDL was found to give maximal inhibition of Neuro2a cell differentiation under serum-free conditions. In contrast, treatment with LDL containing the same concentration of cholesterol did not block neuroblastoma differentiation after serum withdrawal (Figure 4b ).
We next assessed whether HDL might block the ability of LPDS to trigger neuroblastoma differentiation. As shown in Figure 4c , this was indeed the case.
Addition of HDL (containing 80 mg/ml cholesterol) to medium containing 10% LPDS blocked the differentiation of Neuro2a cells.
The experiments in Figure 3 showed that Neuro2a differentiation after serum withdrawal was due to the activation of MAPKs and PI3K/Akt. To evaluate whether HDL was involved in serum-withdrawal induced Akt-and MAPK phosphorylation, cells were switched to serum-free conditions for 1 h, with or without the addition of 80 mg/ml HDL, and Akt and ERK1/2 phosphorylation was evaluated by immunoblotting. As shown in Figure 4d , the addition of HDL indeed decreased the amount of phosphorylated Akt and ERK1/2 after serum withdrawal.
Activation of EGFR is necessary for neuroblastoma differentiation after serum withdrawal Activated ERK1/2 and Akt are typically found downstream of RTKs. A key nexus in signal transduction is the EGFR, which is well known to undergo transactivation in response to a plethora of different stimuli Signalling leading to neuroblastoma differentiation ME Evangelopoulos et al (Fischer et al., 2003) . We speculated that serum withdrawal might also activate EGFR in our experimental system. Thus, we probed blots of Neuro2a lysates undergoing differentiation with an antibody specific for phosphorylated EGFR (Tyr-1068). As shown in Figure 5a , serum withdrawal was indeed associated with a time-dependent and persistent increase in pEGFR, detectable at 30 min after serum removal.
The EGFR family consists of four members. ErbB2 (also called HER2 or c-Neu), originally cloned from neuroblastoma, heterodimerizes with EGFR (Alroy and Yarden, 1997) . It is thought that this RTK does not possess its own high-affinity ligand; instead it may play a role in enhancing EGFR signalling. Therefore, we examined whether serum withdrawal also leads to tyrosine-phosphorylation of this receptor at Tyr-877. As shown in Figure 5a , this was indeed the case. ErbB2 was activated at the earliest time point examined, 5 min after serum withdrawal.
Is the activation of EGFR after serum withdrawal blocked by addition of HDL? To test this, we performed an HDL repletion experiment as described earlier (Figure 4b ). Neuro2a cells were switched to serum-free medium for 24 h in the presence or absence of HDL (containing 80 mg/ml cholesterol). As shown in Figure 5b , the presence of HDL blocked the activation of EGFR in response to serum withdrawal.
After having established serum-withdrawal induced activation of EGFR, we tested whether the phosphorylation of EGFR was not only associated, but also required for the serum-withdrawal induced differentiation. Neuro2a cells were treated with Tyrphostin-25, a frequently used compound that abrogates EGFR activation (Gazit et al., 1989) . Interestingly, pharmacological inhibition of EGFR signalling blocked differentiation (Figure 5c ), without compromising viability (data not shown). The same result was obtained when cells were transfected with a dominant-negative EGFR construct (Figure 5d ). This finding was perhaps somewhat surprising, as EGFR is most commonly known for its proliferationinducing effects, for example on breast cancer cells (Ullrich, 2002) . On the other hand, our results are in line with previous studies that reported that EGFR, even though it promotes the initial proliferation of neuronal stem cells in culture, at later stages induces the neuronal differentiation of these cells (Wong and Guillaud, 2004 ).
Next, we tested whether addition of the EGFR inhibitor, Tyrphostin-25, affects activation of ERK1/2 and Akt after serum withdrawal (Figure 5e) . Indeed, the addition of this EGFR blocker for 1 h strongly inhibited the activation of Erks and significantly attenuated the activation of Akt.
Discussion
Certain cell types such as myoblasts , glioma cells (Fan, 1983) , neuroblastoma cells or neuronal stem cells (Conti et al., 2001) grown in vitro differentiate after serum withdrawal. The signalling mechanisms involved in neuroblastoma differentiation after serum-withdrawal are largely unknown. In the present study, we analysed the biochemical mechanisms using murine Neuro2a cells as a model.
Our initial analysis based on Western blotting with antibodies to some important phosphorylated kinases revealed a rapid activation of Akt and ERK1/2 in cells undergoing serum withdrawal. Thus, the neuronal differentiation of neuroblastoma cells after serum withdrawal has similarities to pathways of neuronal differentiation in other well-established models, such as neurite outgrowth by PC12 pheochromocytoma cells, induced by nerve growth factor (NGF) mediated activation of its receptor TrkA.
As is the case for NGF stimulated PC12 cells, inhibitors of both the PI3K/Akt and MAPK pathways blocked neuronal differentiation in our model. In light of this it appears interesting that two previous studies demonstrated an involvement of the transcription factors NGF-1A and C/EBPbeta in serum-withdrawal induced differentiation of Neuro2a cells (Pignatelli et al., 1999; Cortes-Canteli et al., 2002) . These observations fit well into the mechanistic framework outlined by us, as both transcription factors are known to be downstream of the Ras/Raf/MEK/ERK1/2 or PI3K/Akt modules. and wt-EGFR þ GFP (wt-EGFR). The next day, cells were subjected to serum withdrawal by switching from DMEM/FCS ( þ serum) to DMEM/BSA (serum-free) for 48 h. (e) Treatment with an EGFR inhibitor blocks serum-withdrawal induced ERK1/2 and Akt activation. Neuro2a cells were subjected to serum withdrawal by switching from DMEM/FCS ( þ serum) to DMEM/BSA (serum-free) in the presence or absence of Tyrphostin-25 (200 mM) for 1 h. Subsequently, cells were lysed and equal amounts of lysate subjected to immunoblotting with antibodies against pAkt or pERK1/2. Subsequently, membranes were stripped and re-probed with antibodies against ERK1/2 or Akt as loading control Unexpectedly, our findings suggest that HDL is a serum-derived agent, whose removal is causally related to the serum withdrawal induced differentiation of Neuro2a cells. In support of this hypothesis, addition of HDL (but not LDL) blocked differentiation after serum withdrawal and inhibited the serum deprivation induced activation of EGFR, which is necessary for serum-withdrawal induced differentiation. HDL is a lipoprotein particle of 8-10 nm that contains different apolipoproteins (Apo-A, -C, -D) as well as triglycerides and cholesterol. Any of these constituents might be responsible for the inhibition of Neuro2a differentiation. It has been previously proposed that HDL might act as a signalling 'growth factor' (Fidge, 1999) . Alternatively, HDL might exert its profound effect solely via cholesterol delivery to cells. At first glance, this latter possibility seems unlikely as the cholesterol containing LDL particles failed to block differentiation. However, it is important to note that there are significant differences in the lipoprotein physiology between humans and rodents. In humans, LDL represents the classical cholesterol delivery shuttle whereas HDL is regarded as a cholesterol removal vehicle. However, the opposite is the case in rodents (Fidge, 1999) . As Neuro2a cells are murine cells, further studies are necessary to dissect whether the inhibition of Neuro2a differentiation by HDL is caused by HDL signalling or cholesterol delivery. In addition, it will be necessary to address whether serum withdrawal alters the partition of EGFR to cholesterol-containing lipid rafts. This could represent a potential upstream mechanism for EGFR activation in our experimental system, as raft disruption is known to trigger EGFR activation in non-neuronal cell lines (Furuchi and Anderson, 1998) , although the upstream mechanisms are unknown (Westover et al., 2003) .
Although our finding that lipoproteins block the differentiation of neuroblastoma cells is in line with the classical observation that tumour cells accumulate high levels of cholesterol (Li et al., 2003) and that HDL promotes proliferation of tumour cells, our study seems to be at odds with an important paper by Pfrieger and co-workers. These authors found that neurons depend on glia-derived ApoE containing lipoprotein for efficient neuronal differentiation (Mauch et al., 2001) . One potential explanation for this apparent discrepancy might be a cell-type-specific difference between Neuro2a neuroblastoma cells and the primary rat retinal ganglion neurons used by these authors. Alternatively, one might speculate that different lipoproteins play different roles at different stages during neuronal development. Potentially, lipoproteins are important for proliferation of neuronal precursors (or neuroblastoma cells) early in development, whereas later, after cell cycle arrest and initial neuronal differentiation, it might become important for the proper assembly of numerous synapses by delivering the necessary large amounts of cholesterol.
The observation that serum withdrawal triggered the tyrosine phosphorylation of EGFR and of its family member ErbB2 was surprising. The PI3K/Akt and Ras/ Raf/MEK/ERK1/2 modules are commonly found downstream of RTKs (such as the EGFR or ErbB2), and, therefore, it appears possible that EGFR/ErbB2 activation is the most proximal signalling event in our cascade identified so far. Indeed, blocking EGFR also blocked activation of Akt and ERK1/2 as well as differentiation after serum withdrawal. However, although the EGFR inhibitor Tyrphostin-25 blocked activation of Akt and ERK1/2 after serum withdrawal, bands corresponding to the phosphorylated EGFR (but not to pErbB2) appeared temporally later than those of pERK1/2 and pAkt. A rather trivial possible explanation might be that our phosphorylation-site specific antibody for pEGFR (Tyr-1068) was less sensitive in immunoblotting than those used for pERK1/2 and pAkt. Alternatively, EGFR is being activated by another, more upstream event that triggered activation of ERK1/2 and Akt before inducing activation of EGFR. Indeed, according to the literature, EGFRs are well known to be transactivated. For example, EGFRs might become phosphorylated secondary to stimulation of cells with a very diverse array of ligands unrelated to EGF, such as phorbolester, RA, G-protein coupled receptors, and other growth factor receptors including those for platelet-derived growth factor (PDGF) or growth hormone (GH) (Fischer et al., 2003) . As phorbolester, forskolin and RA are well-established differentiation inducing agents for neuroblastoma cells, it should be examined whether transactivated EGFR is also causally involved in neuroblastoma differentiation triggered by these agents. Interestingly, a recent paper reported a rapid activation of ERK1/2 and CREB in neuronal cells treated with RA (Canon et al., 2004) .
In summary, our study sheds light on the biochemical mechanisms leading to neuroblastoma differentiation after serum withdrawal, implicating well-known players such as EGFR, ErbB2, ERK1/2 and Akt in this process. In addition, we found evidence for a mechanistic link between serum depletion and lipoprotein removal in this experimental system. There are some medically relevant implications from our in vitro data. First, nutritional factors and cholesterol metabolism might play a role in the clinical outcome of neuroblastoma patients. Second, pharmacological interventions aimed at the mechanisms of neuroblastoma differentiation outlined in this study might be therapeutically relevant. Third, our results raise the question whether lipoproteins and EGFR also play a role in the differentiation of other cell types known to differentiate after serum withdrawal.
Materials and methods
Reagents
PD98059 was purchased from Calbiochem (San Diego, CA, USA). Tyrphostin-25 was from Biomol (Plymouth Meeting, PA, USA). LY294002 was purchased from Sigma (St Louis, MO, USA). Inhibitors were dissolved in DMSO.
Cell culture conditions and pharmacological treatments
Neuro2a cells (CLL-131) were obtained from ATCC. Only cells with passage number o20 were used. Cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) containing 10% heat-inactivated FCS (Gibco) and penicillin/streptomycin (Gibco), at 371C and 5% CO 2 . According to the vendor, the FCS used by us contained cholesterol at concentrations ranging between 22 and 38 mg/100 ml. This translates into 22-38 mg/ml in our culture medium, which was DMEM containing 10% FCS (DMEM/FCS).
For differentiation assays, cells were seeded out at 5000 cells per well the day before the experiment in DMEM/FCS on 24-well plates coated with poly-L-lysine, and switched to prewarmed DMEM containing 0.1% BSA (DMEM/BSA) at the following day to trigger differentiation. For drug treatments, cells were preincubated for 1 h in regular culture medium (DMEM/FCS) containing the compounds described. Subsequently, serum was removed by switching to DMEM/ BSA with or without inhibitors, and cells were incubated for an additional 24 h.
To evaluate the role of lipoproteins on differentiation, cells were incubated for 24 h with DMEM containing either 10% lipoprotein-deficient fetal calf serum ('LPDS', Sigma) or DMEM containing 10% FCS ('full serum').
To analyse the effects of cholesterol repletion on differentiation under serum-free conditions, cells were subjected to serum withdrawal and incubated in DMEM/BSA in the presence or absence of purified HDL or LDL (Calbiochem, final concentration of cholesterol: 80 mg/ml), for 24 h.
To analyse the effect of cholesterol repletion on the activation of kinases, cells were subjected to serum withdrawal by switching to DMEM/BSA for 1 h in the presence or absence of purified HDL (cholesterol 80 mg/ml). Subsequently, cells were lysed, and immunoblotting was performed as described below.
For all pharmacological treatments, a LIVE/DEAD-Viability/Cytotoxicity Kit (Molecular Probes) was used to assess the viability of treated cells. Viable green fluorescent cells or dead red cells were visualized using a Nikon Eclipse TE300 fluorescence microscope.
Transfections
Neuro2a cells were transfected with mammalian expression plasmids encoding cDNAs for dominant-negative Akt/PKB (pMT2HA-PKB-CAAX) (van Weering et al., 1998) , dominant-negative Ras (pMT2HA-Ras N17) (de Vries-Smits et al., 1992), wt-EGFR and dominant-negative EGFR (Livneh et al., 1986) and pEGFP-N1 (Clontech). LipofectAMINE 2000 (Gibco) was used according to the manufacturer's instructions.
Biochemical methods
Differentiation of Neuro2a was triggered by serum withdrawal. After different time points, cells were washed twice with ice cold phosphate-buffered saline (PBS) and then lysed.
Protein concentrations were determined using a BCA kit (Pierce). Equal amounts of protein (10 mg) were separated on SDS-PAGE and subjected to immunoblotting as previously described (Evangelopoulos et al., 2004) .
Membranes were probed overnight at 41C with the following antibodies: anti-neuronal nuclei (NeuN) (Chemicon, Temecula, CA, USA), anti-phospho-Akt (phospho-Ser 473) (Cell Signalling Technology, CST, Beverly, MA, USA), antiAkt (CST); anti-phospho-ERK 1/2 (CST); anti-ERK 1/2 (Transduction Laboratories), anti-c-Raf (Transduction Laboratories); anti-phospho-Raf (Ser259) (CST), anti-phospho-EGFR (Tyr-1068) (CST), anti-phospho-ErbB2 (Tyr-877) (CST), anti-CREB (CST), anti-phospho-CREB (Upstate, Lake Placid, NY, USA), anti-c-Fos (Santa Cruz, Biotechnology), anti-tubulin (Sigma) and anti-chromogranin B (Santa Cruz, Biotechnology).
After incubation with primary antibodies, membranes were washed three times for 10 min with TBS-T and then incubated for 1 h with the appropriate anti-mouse-or anti-rabbit horseradish peroxidase-conjugate secondary antibodies (Pierce). Blots were washed and developed using chemoluminescence reagent (Pierce) and exposed to X-ray films (Kodak). Each experiment was repeated three times with similar results. Blots were stripped using a 'Re-blot Plus' kit from Chemicon.
Statistical analysis
All experiments were performed at least three times. All values are presented as mean7standard error of the mean. Statistical comparisons of the mean values were performed with Student's t-test. Differences were considered to be statistically significant with P-values p0.05. All statistical analyses were performed with the software package PRISM.
Abbreviations RTK, receptor tyrosine kinase; EGFR, EGF receptor; MAPK, mitogen-activated protein kinase; PKB/Akt, protein kinase B/Akt; PBS, phosphate-buffered saline; CREB, cAMPresponsive element binding protein; TBS, Tris-buffered saline.
